Related Experiment Videos
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response
Insights
This study introduces a new in vitro method to measure rubidium-86 (86Rb) uptake in human red blood cells. Digoxin treatment for arrhythmias reduced 86Rb uptake, correlating better with therapeutic response than plasma levels.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiology
Background:
- Atrial fibrillation and fast arrhythmias are common cardiac conditions.
- Digoxin is a medication used to control heart rate in these conditions.
- Measuring drug efficacy and patient response is crucial in clinical practice.
Purpose of the Study:
- To describe an in vitro technique for measuring 86Rb uptake in human erythrocytes.
- To investigate the effect of digoxin treatment on 86Rb uptake in patients with arrhythmias.
- To compare the correlation of 86Rb uptake changes with therapeutic response versus plasma digoxin concentrations.
Main Methods:
- Development of an in vitro assay to quantify 86Rb uptake by human erythrocytes.
- Recruitment of fifteen patients diagnosed with atrial fibrillation or other fast arrhythmias.
- Administration of digoxin to patients and measurement of 86Rb uptake pre- and post-treatment.
Main Results:
- The described in vitro technique allows for the measurement of 86Rb uptake in human red blood cells.
- Digoxin treatment led to a significant decrease in 86Rb uptake in the erythrocytes of treated patients.
- Changes in 86Rb uptake showed a stronger correlation with the therapeutic effectiveness of digoxin in atrial fibrillation patients compared to plasma digoxin levels.
Conclusions:
- The in vitro 86Rb uptake assay is a viable method for assessing cellular drug effects.
- Digoxin digitalization impacts erythrocyte 86Rb uptake, suggesting cellular mechanisms beyond plasma concentration.
- Erythrocyte 86Rb uptake may serve as a more sensitive biomarker for digoxin's therapeutic efficacy in arrhythmias.
Abstract:
1 An in vitro technique is described for measuring the uptake of 86Rb by human erythrocytes. 2 Fifteen patients were treated with digoxin for atrial fibrillation and other fast arrhythmias. 3 86Rb uptake by the patients' own red cells fell from pre-treatment values during digitalization. 4 The therapeutic response of patients with atrial fibrillation correlated better with the changes in 86Rb uptake than with plasma digoxin concentrations.